ES2053890T3 - Agente inhibidor de la angiogenesis. - Google Patents

Agente inhibidor de la angiogenesis.

Info

Publication number
ES2053890T3
ES2053890T3 ES89116053T ES89116053T ES2053890T3 ES 2053890 T3 ES2053890 T3 ES 2053890T3 ES 89116053 T ES89116053 T ES 89116053T ES 89116053 T ES89116053 T ES 89116053T ES 2053890 T3 ES2053890 T3 ES 2053890T3
Authority
ES
Spain
Prior art keywords
angiogenesis inhibiting
inhibiting agent
angiogenesis
prophylaxis
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89116053T
Other languages
English (en)
Inventor
Shoji Kishimoto
Takeshi Fujita
Tsuneo Kanamaru
Moses Judah Folkman
Donald Ingber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Childrens Medical Center Corp
Original Assignee
Takeda Chemical Industries Ltd
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd, Childrens Medical Center Corp filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ES2053890T3 publication Critical patent/ES2053890T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DERIVADOS DEL FUMAGILOL O - SUSTITUIDO Y SUS SALES TIENEN UNA ADITIVIDAS INHIBIDORA DE ANGIOGENESIS Y SON UTILES PARA PROFILASIS Y TRATAMIENTO DE ENFERMEDADES PRODUCIDAS POR UNA NEOVASCULARIZACION ESTIMULADA ANORMALMENTE
ES89116053T 1988-09-01 1989-08-31 Agente inhibidor de la angiogenesis. Expired - Lifetime ES2053890T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21928788 1988-09-01
JP5353789 1989-03-06
US39198089A 1989-08-10 1989-08-10

Publications (1)

Publication Number Publication Date
ES2053890T3 true ES2053890T3 (es) 1994-08-01

Family

ID=27294982

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89116053T Expired - Lifetime ES2053890T3 (es) 1988-09-01 1989-08-31 Agente inhibidor de la angiogenesis.

Country Status (6)

Country Link
EP (1) EP0357061B1 (es)
KR (1) KR0141692B1 (es)
AT (1) ATE106726T1 (es)
CA (1) CA1329771C (es)
DE (1) DE68915900T2 (es)
ES (1) ES2053890T3 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
ES2099064T3 (es) * 1988-09-01 1997-05-16 Takeda Chemical Industries Ltd Derivados de fumagillol.
TW282399B (es) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
EP0470569B1 (en) * 1990-08-08 1995-11-22 Takeda Chemical Industries, Ltd. Intravascular embolizing agent containing angiogenesis inhibiting substance
NZ240214A (en) 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
DE69231457T2 (de) * 1991-06-21 2001-05-23 Takeda Chemical Industries Ltd Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate
US6011024A (en) 1991-08-28 2000-01-04 Imperial College Of Science Technology & Medicine Steroid sulphatase inhibitors
US6476011B1 (en) 1991-08-28 2002-11-05 Sterix Limited Methods for introducing an estrogenic compound
US6903084B2 (en) 1991-08-29 2005-06-07 Sterix Limited Steroid sulphatase inhibitors
EP0608419A4 (en) * 1991-09-18 1995-01-11 Fujisawa Pharmaceutical Co TRANSOCULAR PREPARATION.
JPH06157344A (ja) * 1992-02-07 1994-06-03 Childrens Medical Center Corp:The 血管新生阻害のための医薬製剤及び血管新生阻害方法
ES2110573T3 (es) 1992-08-07 1998-02-16 Takeda Chemical Industries Ltd Produccion de microcapsulas de farmacos solubles en agua.
EP0602586B1 (en) * 1992-12-16 1997-06-04 Takeda Chemical Industries, Ltd. Stable pharmaceutical composition of fumagillol derivatives
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6114355A (en) * 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US8143283B1 (en) 1993-03-01 2012-03-27 The Children's Medical Center Corporation Methods for treating blood-born tumors with thalidomide
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US5290887A (en) * 1993-04-30 1994-03-01 The Dow Chemical Company Epoxy resins containing thiadiazole and/or oxadiazole moieties
US5387657A (en) * 1993-09-10 1995-02-07 The Dow Chemical Company Epoxy resins containing thiadiazole and/or oxadiazole moieties
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
DE69519685T2 (de) * 1994-09-30 2001-08-02 Takeda Chemical Industries Ltd Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
US5710148A (en) * 1995-03-06 1998-01-20 Senju Pharmaceuticals Co., Ltd. Corneal opacification inhibitory composition
US5837281A (en) 1995-03-17 1998-11-17 Takeda Chemical Industries, Ltd. Stabilized interface for iontophoresis
FR2733499B1 (fr) * 1995-04-27 1997-05-30 Adir Nouvelles tetrahydropyrano(3,2-d)oxazolones substituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2733498B1 (fr) * 1995-04-27 1997-05-30 Adir Nouveaux composes cyclohexaniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0813887A3 (en) * 1996-06-20 1999-11-03 Hisamitsu Pharmaceutical Co. Inc. A device structure for iontophoresis
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
WO1998005293A2 (en) * 1996-08-02 1998-02-12 The Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
AU746713B2 (en) 1996-11-05 2002-05-02 Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
US6673828B1 (en) 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
KR100357542B1 (ko) * 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
KR100357541B1 (ko) * 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
JP4414517B2 (ja) 1999-09-01 2010-02-10 久光製薬株式会社 イオントフォレーシス用デバイス構造体
US7335650B2 (en) 2000-01-14 2008-02-26 Sterix Limited Composition
JP4212356B2 (ja) 2000-11-01 2009-01-21 プラエシス ファーマシューティカルズ インク． 血管新生を調節するための治療薬およびその使用方法
US7105482B2 (en) 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
US6919307B2 (en) * 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
PT1353672E (pt) 2000-11-30 2008-01-11 Childrens Medical Center Síntese da 4-amino talidomida enantiómeros
KR100455900B1 (ko) * 2001-09-27 2004-11-12 주식회사 아이디알 새로운 푸마질롤 유도체 및 그의 제조방법
EP1436286B1 (en) * 2001-09-27 2009-08-19 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof
US6803382B2 (en) 2001-11-09 2004-10-12 Galderma Research & Development, S.N.C. Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
FR2832149B1 (fr) * 2001-11-09 2006-01-06 Galderma Res & Dev Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique
WO2010065877A2 (en) * 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
BR112019024135A2 (pt) 2017-05-18 2020-06-02 Tesaro, Inc. Terapias de combinação para o tratamento de câncer
WO2019067978A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. POLYTHERAPIES FOR THE TREATMENT OF CANCER
SG11202002499TA (en) 2017-10-06 2020-04-29 Tesaro Inc Combination therapies and uses thereof
WO2019118612A1 (en) * 2017-12-12 2019-06-20 Zafgen, Inc. Targeting compounds
WO2023156996A1 (en) * 2022-02-16 2023-08-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Metap2 inhibitors and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325199B1 (en) * 1988-01-19 1993-10-27 Takeda Chemical Industries, Ltd. Fumagillin as angiostatic agent

Also Published As

Publication number Publication date
ATE106726T1 (de) 1994-06-15
KR900004333A (ko) 1990-04-12
EP0357061B1 (en) 1994-06-08
CA1329771C (en) 1994-05-24
DE68915900T2 (de) 1994-11-24
KR0141692B1 (ko) 1998-06-01
DE68915900D1 (de) 1994-07-14
EP0357061A1 (en) 1990-03-07

Similar Documents

Publication Publication Date Title
ES2053890T3 (es) Agente inhibidor de la angiogenesis.
DE3382458D1 (de) Haarwuchsmittel.
NO905201D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzofuran-derivater.
NO942641L (no) Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav
NO912758D0 (no) Anvendelse av det virksomme stoffet flupirtin for bekjempelse av muskelspenninger.
NO172389C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzotiazoler
NO160369C (no) Analogifremgangsmaate for fremstilling av nye, terapeutiskaktive 1,3-dihydro-6-(1-hydroksy-2-dimetylaminometyl-allyl)-7-hydroksy-furo(3,4-c)-pyridinderivater.
DE68907423D1 (de) Behandlung der akne.
DK599789A (da) 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,3,4-thiadazoler og -oxadiazoler samt 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,2,4-thiadazoler, -oxadiazoler og -triazoler som anti-inflammatoriske midler
DE69010162D1 (de) Zusammensetzung zur Behandlung von Entzündung.
NO170886C (no) Analogifremgangsmaate for fremstilling av nye terapeutisk aktive benzotiofener
NO171412C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-oksatiolan- eller 1,3-ditiolanderivater
DE69130586D1 (de) Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
NO165545C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive nye oksadiazolimidazo-benzodiazepinderivater.
DE69032000T2 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
IT7822027A0 (it) Apparecchio medicale per la cura della trombosi venale profonda.
DE3587978D1 (de) Mittel zur Behandlung von Erkrankungen der Venen und des Analbereichs.
DE69115745D1 (de) Verwendung von Steroidderivaten zur Behandlung der Endometriose
DE69023459T2 (de) Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten.
ES2032797T3 (es) Agente terapeutico para el tratamiento de la enfermedad ulcera peptica.
NO163777C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive dioksino-(4,5-c)-pyridin-derivater.
FI880775A0 (fi) Kraftanlaeggning med foerbraenning av ett braensle i en fluidiserad baedd.
NO884635L (no) Fremgangsmaate for behandling av voerter.
ES2078305T3 (es) 2-alquil-3-benzoilbenzofuranos utiles para el tratamiento de la arritmia cardiaca.
DE69001988D1 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 357061

Country of ref document: ES